Aerie Names David Hollander Chief Research & Development Officer

Xconomy Raleigh-Durham — 

David Hollander is joining Aerie Pharmaceuticals (NASDAQ: AERI) as chief research and development officer. Hollander most recently worked at Ora, where he was chief medical officer and senior vice president. His experience also includes more than a decade at Allergan (NYSE: AGN). Durham, NC-based Aerie has two FDA-approved glaucoma treatments: netarsudil (Rhopressa) and the netasudil and latanoprost combination therapy marketed as Rocklatan.